BioSpace News Archive

Repertoire Immune Medicines, a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D).

Sol-Gel Technologies, Ltd. today announced plans to present an overview of the Company and provide a business update at the upcoming Solebury Trout Virtual Investor Conference. The 25 minute presentation includes an interactive

Parallax Announces Patented Telehealth Initiative to Help Healthcare Providers Better Communicate with Their Patients and Reduce ER Admissions

Stratify Genomics Inc., makers of the Prompt Prostate Genetic Score test for Prostate Cancer risk assessment, announced their support of doctors across the country in their unprecedented but necessary shift to telemedicine while at the same time continuing to care for their patients during the COVID-19 outbreak.

4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors

New lab results from BLUEWAVE Technologies, Inc. indicate that when used as directed, its BLUEWAVE device can effectively kill the non-enveloped virus, MS2 Bacteriophage, and Methicillin Resistant Staphylococcus Aureus..

Specialty Renal Products, Inc., a subsidiary of Nephros, Inc., a medical device company that develops and sells a hemodiafiltration system for the treatment of patients with end stage renal disease, announced that it has hired Tony Robinson as Vice President of Operations.

Novel pharmaceutical Vicromax(tm)* has already undergone extensive animal testing and human clinical experience in other indications

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it has completed the REST-ON Phase 3 clinical trial for FT218.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that nine posters on ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection will be available online during and after the 11 th Annual Congress on Controversies in Ophthalmology (COPHy) conference beginnin